SCHEMBL3868065

SCHEMBL3868065

CCCCC(=O)O[C@H]1CCC2C3CCc4cc(OC(=O)c5cccc(S(N)(=O)=O)c5)ccc4C3CC[C@@]21C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
KMT2A Q03164 6/20 0.66
LMNA P02545 6/20 0.66
CYP3A4 P08684 5/20 0.66
MEN1 O00255 4/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
TP53 P04637 4/20 0.66
ESR1 P03372 4/20 0.66
ADORA3 P0DMS8 3/20 0.66
ATM Q13315 2/20 0.66
ALOX15 P16050 2/20 0.66
PGR P06401 2/20 0.66
AR P10275 2/20 0.66
PTGS1 P23219 2/20 0.66
PDE3A Q14432 2/20 0.66
POLB P06746 1/20 0.66
CHRM1 P11229 1/20 0.66
TBXA2R P21731 1/20 0.66
USP2 O75604 1/20 0.66
THRB P10828 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866528 0.90 SMN1; SMN2 (0.64) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL3870740 0.88 KMT2A (0.68) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL3864661 0.88 KMT2A (0.68) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL146888 0.86 LMNA (0.82) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL3876321 0.86 SMN1; SMN2 (0.72) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL2596563 0.86 LMNA (0.71) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL9404738 0.85 LMNA (0.79) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL3870726 0.84 ESR1 (0.69) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL8465006 0.84 MAPT (0.79) MAPTKMT2ALMNACYP3A4MEN1
SCHEMBL4265262 0.83 MAPT (0.77) MAPTKMT2ALMNACYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534780-B2 Estradiol prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-05-19 US claimed
US-20050288267-A1 Estradiol prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-12-29 US claimed
US-7534780-B2 Estradiol prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-05-19 US disclosed
US-20050288267-A1 Estradiol prodrugs BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288267-A1 Estradiol prodrugs CYP19A1, ESR1, HSD17B11 MAPT 3210/4885KMT2A 2558/4885LMNA 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.